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This Special Issue on Cancer Nanomedicine within Cancers brings together 46 cutting-edge papers
covering research within the field along with insightful reviews and opinions reflecting our community.
Cancer nanomedicine is a large umbrella under which researchers explore the physical, chemical and
biological sciences. I think this is well reflected in this edition. Cancer treatments are often hindered
by the lack of drug specificity, poor physicochemical properties of active pharmaceutical ingredients,
poor penetration ability and drug resistance. With the discovery and characterization of an increasing
number of cancer types with little improvement of the ability to diagnose, treatment options or patient
prognosis, more advanced technologies are urgently required. Nanotechnology defines particulates
within the 1 × 10−9 m range. Particulates within the nano-sized domain often exhibit unique properties
compared to their larger size scale. These can be exploited in biomedicine for applications such as imaging,
cell sorting, drug delivery and targeting. Cancer nanomedicine is rapidly becoming one of the leading
areas of promise for cancer therapy, with first-generation treatments already available to patients.
Within this Special Issue, a diverse range of cancer nanomedicines have been discussed,
including the more traditional organic-based systems, such as lipid [1–6], polymer [7–11] and
cyclodextrin-based [12] particulates. Additionally, there are multiple studies from the growing
area of inorganic systems, such as carbon nanomaterials (such as graphene oxide [13,14] and carbon
nanotubes [15]) as well as other more established metallic nanomaterials, such as gold [16,17],
iron oxide [18,19] and silica-based [20,21] systems. Interest into such inorganic systems has boomed
over the last ten years, largely down to their multifunctional capabilities, in imaging [15], photothermal
ability [22,23] or use in radiation enhancement [24]. Within this arena, a new class of nanoplatform has
also developed, which is gaining traction. These platforms can be used for combined diagnostics and
therapy, known as theranostics. The theranostic community is growing rapidly and in this issue a
review of theranostics under development [25] as well a scientific paper [20] have been included.
One of the major challenges in cancer nanomedicine is tumour targeting and penetration.
Conjugation of surface targetingligands, peptides and other molecules are of major focus within this
field [26], including the use of TAT peptides [27], vitamins such as riboflavin [28], integrins [29] and
antibodies [30]. Other issues such as tumour microenvironment also contribute to such challenges,
and discussion on nanomedicine uptake looking at mechanistic evaluations such as shear stress [31],
a hypoxic environment [32] and in overexpressing cell lines [33] have also been included.
Rapid clearance via the immune system has been another barrier historically faced by
nanotechnologies. As such, nanomedicines have been developed that are inspired by or mimetic
of biological systems such as extracellular vesicles [34] and exosomes [35] that exploit the naturally
occurring nano vehicles produced inside the body to extract and repurpose as drug delivery systems.
Other clever systems utilise other biomolecules in order to protect their nanoparticle payload, such as
cloaking with cell membranes [36]. Other systems seek to deliver biomolecules such as siRNA [37,38]
or to elicit an immune response in order to combat cancer [37–41].
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Combination therapy has shown major improvement in chemotherapy compared with
monotherapy. With improved tumour retardation, reduced drug resistance and better patient prognosis.
As such, nanomedicines are under development incorporating combination therapies [30,42] in the
hope to further enhance the findings found in small molecule trials, with the protective capabilities
of nanomedicines through targeting techniques in order to reduce the toxic side effects of the potent
compounds attributed to systemic circulation.
As the benefits of nanomedicine for cancer therapy have been realised, the incorporation of such
nanotechnologies has been incorporated into larger-scale macromolecular systems. One such example
is in the use of microbubbles [43]. Here, the nanotechnologies are conjugated onto the microbubble
surfaces and ultrasonic energy is used as a means to cavitate the tumour tissue, allowing for deeper
penetration of the nanomedicines in order for them to deliver their payload at the site of need.
As many of the cancer nanomedicines under development translate further towards the clinic,
investigation on reliable scale-up and manufacture is explored. One technique that is currently
dominating this field, particularly in liposomal development, is microfluidics. In this issue, we
highlight its use in the manufacture of folate conjugated albumin particles incorporating Cabazitaxel [44].
The highly engineered mixing techniques and continuous flow parameters make such technology ideal
for the formulation of cancer nanomedicines in the large batches required for trials and beyond. Work is
ongoing globally into the evaluation of whether microfluidics can be exploited for other nanomedicine
development and formulation.
The exciting advances within this field have led to cancer nanomedicines already being used
clinically today. Sceptics would argue that the translation of nanotechnologies into the clinic have
not matched the initial hype, with opinion included on the current state of the cancer nanomedicine
field [45]. I believe, moving forward, more and more commercial success will be achieved. It is
estimated that the global nanomedicine market will be worth USD 334 billion by 2025, with cancer
nanomedicine dominating in this field. As the science develops and leads us down new avenues,
the findings and their meaning are closely scrutinised and debated within the community. This issue
includes 32 scientific manuscripts, 13 review articles and 1 case report reflecting the hot topics within
this area [1–46].
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